AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35860926 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0
Study 35860926 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 0
Study 35861072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital administration of thawed plasma (TP)
Number of subjects: 149
Study 35861129 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0
Study 35861129 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35861296 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose rifampicin (35 mg/kg)
Number of subjects: 128
Study 35861370 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity
Number of subjects: 43
Study 35861464 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in asthma patients
Number of subjects: 11226
Study 35861464 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in COPD patients
Number of subjects: 11226
Study 35861464 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of treatable traits (TTs) in asthma + COPD patients
Number of subjects: 11226
Study 35861464 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TTs prevalence in primary vs specialized clinics
Number of subjects: 11226
Study 35861464 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship of TTs to diagnosis and severity of disease
Number of subjects: 11226
Study 35861464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of TTs presence and absence
Number of subjects: 11226
Study 35861632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab and lenalidomide
Number of subjects: 0
Study 35861632 — intervention group
Group type: COMPARATOR
Intervention: Synthetic control groups
Number of subjects: 0
Study 35861706 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support group participation (3 times weekly for 6 weeks)
Number of subjects: 20
Study 35861778 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (PCZ)
Number of subjects: 10
Study 35861778 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10
Study 35861811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the convalescent group (n=30)
Number of subjects: 90
Study 35861811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the recovered group (n=30)
Number of subjects: 90
Study 35861811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the acute group (n=30)
Number of subjects: 90
Study 35861811 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 90
Study 35861814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) ECG+ (n=74)
Number of subjects: 280
Study 35861814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) ECG- (n=206)
Number of subjects: 280
Study 35861814 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AF)
Number of subjects: 280
Study 35861828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance for PCI
Number of subjects: 2848
Study 35861979 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels
Number of subjects: 6544
Study 35861979 — intervention group
Group type: EXPERIMENTAL
Intervention: High RC/low LDL-C group
Number of subjects: 6544
Study 35861979 — intervention group
Group type: EXPERIMENTAL
Intervention: RC quartiles
Number of subjects: 6544
Study 35861979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 6544
Study 35862024 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 1621
Study 35862034 — intervention group
Group type: EXPERIMENTAL
Intervention: Elo-KRd (elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone)
Number of subjects: 46
Study 35862035 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg 3 times daily) until disease progression, death, or treatment discontinuation.
Number of subjects: 116
Study 35862126 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological variables (depressive symptoms, well-being, quality of life)
Number of subjects: 185
Study 35862126 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological variables (well-being, mental health components of quality of life)
Number of subjects: 185
Study 35862141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT)
Number of subjects: 1829
Study 35862141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI)
Number of subjects: 1829
Study 35862141 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography and hsTnT and hsTnI concentrations
Number of subjects: 1829
Study 35862184 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (BMT4me) designed to promote adherence to immunosuppressant medication and track symptoms
Number of subjects: 15
Study 35862184 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (BMT4me)
Number of subjects: 15
Study 35862185 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring solutions implementation
Number of subjects: 0
Study 35862185 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Acceptance Model questionnaire
Number of subjects: 0
Study 35862692 — intervention group
Group type: EXPERIMENTAL
Intervention: REsOluTioN online resilience training program
Number of subjects: 100
Study 35862692 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 100
Study 35862743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP) 2.1/17.1 mg/kg, administered monthly for 3 consecutive months.
Number of subjects: 82
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncurative ESD for CRC lesions
Number of subjects: 135
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after noncurative ESD
Number of subjects: 135
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncurative ESD for sm1 cancers
Number of subjects: 135
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncurative ESD for >sm1 cancers without risk factors
Number of subjects: 135
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: NC-Lymph score (risk factors for lymph node metastasis)
Number of subjects: 135
Study 35863354 — intervention group
Group type: EXPERIMENTAL
Intervention: NC-Wall score (risk factors for residual lesions in the wall)
Number of subjects: 135
Study 35863672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (level 2 dose at 75 mg/m²), capecitabine, and radiation therapy after induction chemotherapy
Number of subjects: 23
Study 35863672 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I IR
Number of subjects: 23
Study 35863747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) lowering
Number of subjects: 26
Study 35863789 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 10480
Study 35863844 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhythm control (ERC)
Number of subjects: 2785
Study 35864209 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mm Drug-Coated Balloon (DCB)
Number of subjects: 107
Study 35865219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken liver and eggshell crackers
Number of subjects: 0
Study 35865219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35865463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx) testing prior to chemotherapy initiation
Number of subjects: 0
Study 35865463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx) testing
Number of subjects: 0
Study 35865476 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (250 ml/12 h, increased daily to 1000 ml/12 h if tolerated)
Number of subjects: 128
Study 35865476 — intervention group
Group type: COMPARATOR
Intervention: Oral nutrition
Number of subjects: 128
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with regular dental examinations at three-month intervals and preventive treatments (including antibiotics before dental extractions and techniques for wound closure)
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors inserted into the postextraction alveolus plus standardised medical and surgical care
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Delicate surgery and closure by primary intention
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of the extraction socket with a mucoperiosteal flap
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal wound closure
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment in addition to standard care
Number of subjects: 1668
Study 35866376 — intervention group
Group type: COMPARATOR
Intervention: Autofluorescence-guided bone surgery
Number of subjects: 1668
Study 35866376 — intervention group
Group type: COMPARATOR
Intervention: Autofluorescence-guided sequestrectomy
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin after bone surgery
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein-2 with platelet-rich fibrin
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor and primary wound closure
Number of subjects: 1668
Study 35866376 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide 20 μg daily
Number of subjects: 1668
Study 35866376 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 56.5 μg weekly
Number of subjects: 1668
Study 35866563 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVLIM-CP questionnaire
Number of subjects: 89
Study 35866657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 388
Study 35866657 — intervention group
Group type: COMPARATOR
Intervention: No Rocuronium
Number of subjects: 388
Study 35866657 — intervention group
Group type: EXPERIMENTAL
Intervention: AWP presence
Number of subjects: 388
Study 35866984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial PET/CT
Number of subjects: 0
Study 35866984 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial PET/CT
Number of subjects: 0
Study 35866984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cranial and extracranial PET/CT
Number of subjects: 0
Study 35867023 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional 3D Laparoscopes
Number of subjects: 0
Study 35867023 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35867076 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35867239 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcrestal sinus floor elevation with injectable xenograft in gel form
Number of subjects: 71
Study 35867382 — intervention group
Group type: EXPERIMENTAL
Intervention: AR group
Number of subjects: 30
Study 35867385 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (1.1 GBq and 3.7 GBq groups)
Number of subjects: 139
Study 35867393 — intervention group
Group type: EXPERIMENTAL
Intervention: +Change
Number of subjects: 24
Study 35867399 — intervention group
Group type: EXPERIMENTAL
Intervention: SADL-eM (Spinal Cord Injury Activities of Daily Living Education Manual)
Number of subjects: 90
Study 35867399 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 35867399 — intervention group
Group type: EXPERIMENTAL
Intervention: SADL-eM
Number of subjects: 90
Study 35867403 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLUS-D with guidance
Number of subjects: 250
Study 35867403 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLUS-D without guidance
Number of subjects: 250
Study 35867403 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 250
Study 35867411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated health care workers
Number of subjects: 425
Study 35867411 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated health care workers
Number of subjects: 425
Study 35867672 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) monitoring using Cepheid Xpert
Number of subjects: 541
Study 35867672 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) monitoring using Roche COBAS (v2.0)
Number of subjects: 541
Study 35867672 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) monitoring
Number of subjects: 541
Study 35867672 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) monitoring
Number of subjects: 541
Study 35867947 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg orally once daily)
Number of subjects: 46
Study 35867951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks
Number of subjects: 103
Study 35867966 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neuropsychological indicators (age, memory, speed scores)
Number of subjects: 80
Study 35868533 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm inhaled carbon monoxide (CO)
Number of subjects: 0
Study 35868830 — intervention group
Group type: EXPERIMENTAL
Intervention: Admissions to forensic settings
Number of subjects: 0
Study 35868830 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of symptomatology of schizophrenia and violence risk
Number of subjects: 0
Study 35868830 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 0
Study 35868830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient related measures
Number of subjects: 0
Study 35869124 — intervention group
Group type: EXPERIMENTAL
Intervention: Open radical retropubic prostatectomy
Number of subjects: 704
Study 35869124 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 704
Study 35869124 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Number of subjects: 704
Study 35869128 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAL-PLH study (prospective cohort study)
Number of subjects: 0
Study 35869128 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection at two points (2015-2016 and 2020-2021)
Number of subjects: 0
Study 35869143 — intervention group
Group type: EXPERIMENTAL
Intervention: First therapy
Number of subjects: 128
Study 35869143 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent therapies
Number of subjects: 128
Study 35869143 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 128
Study 35869143 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 128
Study 35869170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (180 mg daily for 28 days in cohort 1; 270-360 mg daily for up to 365 days in cohort 2)
Number of subjects: 27
Study 35869170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 27
Study 35869429 — intervention group
Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) in stroke patients
Number of subjects: 1385
Study 35869429 — intervention group
Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) in TBI patients
Number of subjects: 1385
Study 35869429 — intervention group
Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) with abnormal NPi (< 3.0)
Number of subjects: 1385
Study 35869438 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint modeling
Number of subjects: 0
Study 35869438 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage methods (naïve, landmark analysis, time-dependent Cox model, regression calibration)
Number of subjects: 0
Study 35869438 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression calibration
Number of subjects: 0
Study 35869438 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage methods with sample-based measures
Number of subjects: 0
Study 35869500 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLT+PTC (brief online training and post-training consultation)
Number of subjects: 75
Study 35869500 — intervention group
Group type: COMPARATOR
Intervention: Control (services as usual)
Number of subjects: 75
Study 35869557 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 3074
Study 35869557 — intervention group
Group type: COMPARATOR
Intervention: Primary invasive mechanical ventilation (IMV)
Number of subjects: 3074
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS insertion with significant PPG reduction
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS insertion with ascites control
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PPG reduction by TIPS
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PPG after TIPS
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Child-Pugh score before TIPS
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum sodium levels
Number of subjects: 341
Study 35869810 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG reduction
Number of subjects: 341
Study 35869891 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Sleep-related Breathing Disorders (SRBDs)
Number of subjects: 58
Study 35870093 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 833
Study 35870093 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 833
Study 35870093 — intervention group
Group type: COMPARATOR
Intervention: Pneumonia
Number of subjects: 833
Study 35870093 — intervention group
Group type: COMPARATOR
Intervention: Anemia
Number of subjects: 833
Study 35870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 10954
Study 35870177 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 10954
Study 35870368 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prophylaxis regimen with alemtuzumab infusion (5 consecutive days for Course 1, 3 consecutive days for Course 2), including intravenous methylprednisolone 500mg and oral prednisone 50mg, along with oral H1 and H2 antihistaminics.
Number of subjects: 57
Study 35870368 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis regimen with alemtuzumab infusion at Bayshore centers.
Number of subjects: 57
Study 35870472 — intervention group
Group type: EXPERIMENTAL
Intervention: ExtractEHR automated package
Number of subjects: 1077
Study 35870702 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 100 to 400 mg Q4W
Number of subjects: 84
Study 35870702 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 plus NA (with/without JNJ-6379)
Number of subjects: 84
Study 35870702 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 Q4W (200 mg) plus oral JNJ-6379 250 mg daily for 12 weeks
Number of subjects: 84
Study 35870702 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study 35870926 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 4 full-year mean daily school-day MVPA
Number of subjects: 4936
Study 35870926 — intervention group
Group type: COMPARATOR
Intervention: Students attaining 30+ minutes of daily school-day MVPA
Number of subjects: 4936
Study 35870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET), one hour/week individualized exercise during working hours for 12 weeks, with the first 8 weeks supervised and the last 4 weeks home-administered.
Number of subjects: 24
Study 35871040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy (IVC) with gemcitabine
Number of subjects: 345
Study 35871040 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy (IVC) with saline
Number of subjects: 345
Study 35871069 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated carotids
Number of subjects: 26
Study 35871069 — intervention group
Group type: COMPARATOR
Intervention: Control carotids
Number of subjects: 26
Study 35871145 — intervention group
Group type: EXPERIMENTAL
Intervention: Preanestes@s web-based application and PreQuest questionnaire
Number of subjects: 880
Study 35871145 — intervention group
Group type: EXPERIMENTAL
Intervention: Final version of Preanestes@s and PreQuest
Number of subjects: 880
Study 35871310 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 booster vaccination
Number of subjects: 193
Study 35871310 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 193
Study 35871310 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (rituximab, BTKi treatment)
Number of subjects: 193
Study 35871310 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal responses post-second dose
Number of subjects: 193
Study 35871677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women at 26-28 weeks of gestation
Number of subjects: 2491
Study 35871677 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring at birth
Number of subjects: 2491
Study 35871677 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring at 6 years of age
Number of subjects: 2491
Study 35871677 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pregnant women
Number of subjects: 2491
Study 35871677 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid profiles
Number of subjects: 2491
Study 35871922 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) screening tool for sarcopenia
Number of subjects: 118
Study 35871930 — intervention group
Group type: EXPERIMENTAL
Intervention: RWR therapy (liraglutide, leucine-rich amino acid infusion, hypocaloric diet)
Number of subjects: 26